Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Ophthotech

Roche Basel Switzerland

Roche’s Soliris rival Enspryng bags FDA approval

Drug is second to be approved for the treatment of NMOSD

- PMLiVE

AbbVie, Roche’s Venclyxto combo reduces risk of death in first-line AML

Data from the trial has been published in the New England Journal of Medicine

Roche Basel Switzerland

Roche scores FDA approval for SMA drug risdiplam, now named Evrysdi

Drug poised to challenge rivals Spinraza and Zolgensma

- PMLiVE

Tecentriq combo fails in advanced triple negative breast cancer

Tecentriq plus paclitaxel failed to improve progression-free survival

- PMLiVE

Novartis builds its case for novel MS treatment ofatumumab

Detailed results from phase 3 studies published in NEJM

Roche Basel Switzerland

Roche’s Tecentriq combo scores FDA approval for melanoma

Drug approved for patients with BRAF protein mutations

- PMLiVE

Roche pays $120m upfront for UCB’s anti-tau Alzheimer’s drug

Milestone payments could reach up to $2bn

- PMLiVE

Roche’s Actemra fails in late-stage severe COVID-19 study

Anti-inflammatory drug unable to improve clinical status of hospitalised patients

- PMLiVE

Biogen plans Spinraza study in SMA patients treated with Novartis’ Zolgensma

Company aims to extend market reach

Roche Basel Switzerland

Roche cites COVID-19 and biosimilars in Q2 decline

Pharmaceutical sales took a 4% hit in Swiss francs

- PMLiVE

Novartis stumbles in Q2 as COVID-19 impacts sales

Net profit drops by 4% as pandemic hits sales

- PMLiVE

Merck, Bayer get FDA priority review for heart failure drug

Target action date set for January 2021

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links